Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria.

Parisi GF, Papale M, Giovanna Tardino L, Manti S, Cuppari C, Salpietro C, Leonardi S.

J Dermatolog Treat. 2018 Nov 21:1-6. doi: 10.1080/09546634.2018.1551609. [Epub ahead of print]

PMID:
30462557
2.

Omalizumab: a review of its use in patients with chronic spontaneous urticaria.

McCormack PL.

Drugs. 2014 Sep;74(14):1693-9. doi: 10.1007/s40265-014-0290-9. Review.

PMID:
25217402
3.

Treatment of chronic autoimmune urticaria with omalizumab.

Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK.

J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006.

PMID:
18774392
4.

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

Kaplan AP, Giménez-Arnau AM, Saini SS.

Allergy. 2017 Apr;72(4):519-533. doi: 10.1111/all.13083. Epub 2017 Jan 4. Review.

5.

Omalizumab in children.

Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL.

Paediatr Drugs. 2014 Dec;16(6):491-502. doi: 10.1007/s40272-014-0107-z. Review.

6.

Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.

Lang DM.

Drugs Today (Barc). 2015 Jun;51(6):367-74. doi: 10.1358/dot.2015.51.6.2333219. Review.

PMID:
26261850
7.

Profile of omalizumab in the treatment of chronic spontaneous urticaria.

Labrador-Horrillo M, Ferrer M.

Drug Des Devel Ther. 2015 Aug 25;9:4909-15. doi: 10.2147/DDDT.S56004. eCollection 2015. Review.

8.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
9.

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.

Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M.

Theranostics. 2017 Mar 6;7(5):1266-1276. doi: 10.7150/thno.18304. eCollection 2017.

10.

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.

D'Amato G, Salzillo A, Piccolo A, D'Amato M, Liccardi G.

Ther Clin Risk Manag. 2007 Aug;3(4):613-9.

11.

Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.

Giménez-Arnau AM.

Expert Opin Biol Ther. 2017 Mar;17(3):375-385. doi: 10.1080/14712598.2017.1285903. Epub 2017 Feb 9. Review.

PMID:
28125304
12.

Omalizumab may not inhibit mast cell and basophil activation in vitro.

Gericke J, Ohanyan T, Church MK, Maurer M, Metz M.

J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1832-6. doi: 10.1111/jdv.12693. Epub 2014 Sep 26. Review.

PMID:
25257818
14.

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.

Godse K, Rajagopalan M, Girdhar M, Kandhari S, Shah B, Chhajed PN, Tahiliani S, Shankar DS, Somani V, Zawar V.

Indian Dermatol Online J. 2016 Jan-Feb;7(1):6-11. doi: 10.4103/2229-5178.174314. Review.

15.

Omalizumab for chronic urticaria: a case series and overview of the literature.

Ivyanskiy I, Sand C, Thomsen SF.

Case Rep Dermatol. 2012 Jan;4(1):19-26. doi: 10.1159/000336205. Epub 2012 Jan 30.

16.

Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).

D'Amato G, Bucchioni E, Oldani V, Canonica W.

Treat Respir Med. 2006;5(6):393-8.

PMID:
17154668
17.

Comparable actions of omalizumab on mast cells and basophils.

Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea MJ, Martín M, Ferrer M.

Clin Exp Allergy. 2016 Jan;46(1):92-102. doi: 10.1111/cea.12668.

PMID:
26509363
18.

The discovery and development of omalizumab for the treatment of asthma.

Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G.

Expert Opin Drug Discov. 2015;10(9):1033-42. doi: 10.1517/17460441.2015.1048220. Epub 2015 May 15. Review.

PMID:
25979110
19.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.

J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2.

PMID:
21636116
20.

Anti-IgE Treatment for Disorders Other Than Asthma.

Stokes J.

Front Med (Lausanne). 2017 Sep 21;4:152. doi: 10.3389/fmed.2017.00152. eCollection 2017. Review.

Supplemental Content

Support Center